CCL

Összesen 7 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM113899
035-os BibID:(WoS)001042183300001 (Scopus)85168274077
Első szerző:Almayali, Abdullah Ali Hadi
Cím:Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe : placebo-controlled double blind tapering after the GLORIA trial / Abdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, Daniela Opris, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Ed Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, Willem Lems, Yvo Smulders, Maurizio Cutolo, Marieke M. ter Wee
Dátum:2023
ISSN:0003-4967
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 82 : 10 (2023), p. 1307-1314. -
További szerzők:Boers, Maarten Hartman, Linda Opris, Daniela (1976-) (reumatológus) Bos, Reinhard Kok, Marc R. Da Silva, Jose A. P. Griep, Eduard N. Klaasen, Ruth Allaart, Cornelia F. Baudoin, Paul Raterman, Hennie G. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Lems, Willem F. Smulders, Yvo M. Cutolo, Maurizio ter Wee, Marieke M.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM102302
035-os BibID:(WOS)000805325600001 (Scopus)85132198667
Első szerző:Boers, Maarten
Cím:Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+ : the pragmatic randomised, double-blind placebo-controlled GLORIA trial / Maarten Boers, Linda Hartman, Daniela Opris-Belinski, Reinhard Bos, Marc R. Kok, Jose A. P. Da Silva, Eduard N. Griep, Ruth Klaasen, Cornelia F. Allaart, Paul Baudoin, Hennie G. Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol Masaryk, L. Thomas Klausch, Sabrina Paolino, Annemarie M. Schilder, Willem F. Lems, Maurizio Cutolo, GLORIA Trial consortium
Dátum:2022
ISSN:0003-4967
Megjegyzések:Background Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. Methods The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ?1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and those causing study discontinuation. Longitudinal models analysed the data, with one-sided testing and 95% confidence limits (95% CL). Results We randomised 451 patients with established RA and mean 2.1 comorbidities, age 72, disease duration 11 years and DAS28 4.5. 79% were on disease-modifying treatment, including 14% on biologics. 63% prednisolone versus 61% placebo patients completed the trial. Discontinuations were for AE (both, 14%), active disease (3 vs 4%) and for other (including covid pandemic-related disease) reasons (19 vs 21%); mean time in study was 19 months. Disease activity was 0.37 points lower on prednisolone (95% CL 0.23, p<0.0001); joint damage progression was 1.7 points lower (95% CL 0.7, p=0.003). 60% versus 49% of patients experienced the harm outcome, adjusted relative risk 1.24 (95% CL 1.04, p=0.02), with the largest contrast in (mostly non-severe) infections. Other GC-specific events were rare. Conclusion Add-on low-dose prednisolone has beneficial long-term effects in senior patients with established RA, with a trade-off of 24% increase in patients with mostly non-severe AE; this suggests a favourable balance of benefit and harm.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 7 (2022), p. 925-936. -
További szerzők:Hartman, Linda Opris, Daniela (1976-) (reumatológus) Bos, Reinhard Kok, Marc R. Da Silva, Jose A. P. Griep, Eduard N. Klaasen, Ruth Allaart, Cornelia F. Baudoin, Paul Raterman, Hennie G. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Klausch, Thomas Paolino, Sabrina Schilder, Annemarie M. Lems, Willem F. Cutolo, Maurizio GLORIA Trial consortium
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM075623
035-os BibID:(cikkazonosító)e000780 (WoS)000455537200030 (Scopus)85058345877
Első szerző:Dejaco, Christian
Cím:EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology / Christian Dejaco, Polina Putrik, Julia Unger, Daniel Aletaha, Gerolamo Bianchi, Johannes W. Bijlsma, Annelies Boonen, Nada Cikes, Axel Finck, Laure Gossec, Tore K. Kvien, Joao Madruga Dias, Eric L. Matteson, Francisca Sivera, Tanja A. Stamm, Zoltan Szekanecz, Dieter Wiek, Angela Zink, Sofia Ramiro, Frank Buttgereit
Dátum:2018
ISSN:2056-5933
Megjegyzések:Objective: Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these European League Against Rheumatism (EULAR points to consider (PTC) is to guide future workforce studies in adult rheumatology in order to produce valid and reliable manpower estimates. Methods: The EULAR Standardised Operating Procedures were followed. A multidisciplinary task force with experts including patients with rheumatic diseases from 11 EULAR countries and the USA was assembled. A systematic literature review (SLR) was conducted to retrieve workforce models in rheumatology and other medical fields. PTC were based on expert opinion informed by the SLR, followed by group discussions with consensus obtained through informal voting. The level of agreement with the PTC was voted anonymously. Results: A total of 10 PTC were formulated. The task force recommends models integrating supply (=workforce available in rheumatology), demand (=health services requested by the population) and need (=health services that are considered appropriate to serve the population). In general, projections of workforce requirements should consider all factors relevant for current and future workload in rheumatology inside and outside of direct patient care. Forecasts of workforce supply should consider demography and attrition of rheumatologists, as well as the effects of new developments in healthcare. Predictions of future need/demand should take demographic, sociocultural and epidemiological development of the population into account. Conclusion: These EULAR-endorsed PTC will provide guidance on the methodology and the parameters to be applied in future national and international workforce requirement studies in rheumatology.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:RMD Open. - 4 : 2 (2018), p. 1-8. -
További szerzők:Putrik, Polina Unger, Julia Aletaha, Daniel Bianchi, Gerolamo Bijlsma, Johannes W. Boonen, Annelies Cikes, Nada Finck, Axel Gossec, Laure Kvien, Tore K. Dias, João Madruga Matteson, Eric L. Sivera, Francisca Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Wiek, Dieter Zink, Angela Ramiro, Sofia Buttgereit, Frank
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM113494
035-os BibID:(scopus)85159250115 (wos)000871113800001
Első szerző:Hartman, Linda
Cím:Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids / Hartman Linda, da Silva José A. P., Buttgereit Frank, Cutolo Maurizio, Opris-Belinski Daniela, Szekanecz Zoltan, Masaryk Pavol, Voshaar Marieke J. H., Heymans Martijn W., Lems Willem F., van der Heijde Désirée M. F. M., Boers Maarten
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objective: To develop prediction models for individual patient harm and benefit outcomes in elderly patients with RA and comorbidities treated with chronic low-dose glucocorticoid therapy or placebo. Methods: In the Glucocorticoid Low-dose Outcome in Rheumatoid Arthritis (GLORIA) study, 451 RA patients 65 years of age were randomized to 2 years 5 mg/day prednisolone or placebo. Eight prediction models were developed from the dataset in a stepwise procedure based on prior knowledge. The first set of four models disregarded study treatment and examined general predictive factors. The second set of four models was similar but examined the additional role of low-dose prednisolone. In each set, two models focused on harm [the occurrence of one or more adverse events of special interest (AESIs) and the number of AESIs per year) and two on benefit (early clinical response/disease activity and a lack of joint damage progression). Linear and logistic multivariable regression methods with backward selection were used to develop the mod- els. The final models were assessed and internally validated with bootstrapping techniques. Results: A few variables were slightly predictive for one of the outcomes in the models, but none were of immediate clinical value. The quality of the prediction models was sufficient and the performance was low to moderate (explained variance 12?15%, area under the curve 0.67?0.69). Conclusion: Baseline factors are not helpful in selecting elderly RA patients for treatment with low-dose prednisolone given their low power to predict the chance of benefit or harm.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Rheumatology. - 62 : 5 (2023), p. 1824-1833. -
További szerzők:Da Silva, Jose A. P. Buttgereit, Frank Cutolo, Maurizio Opris, Daniela (1976-) (reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Masaryk, Pavol Voshaar, Marieke J. H. Heymans, Martijn W. Lems, Willem F. van der Heijde, Désirée Boers, Maarten
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM105027
035-os BibID:(cikkazonosító)152109 (WoS)001042945400005 (Scopus)85140434684
Első szerző:Hartman, Linda
Cím:Cost-effectiveness and cost-utility of add-on, low-dose prednisolone in patients with rheumatoid arthritis aged 65+ : the pragmatic, multicenter, placebo-controlled GLORIA trial / L. Hartman, M. El Alili, M. Cutolo, D. Opris, J. A. P. Da Silva, Z. Szekanecz, F. Buttgereit, P. Masaryk, R. Bos, M. R. Kok, S. Paolino, V. M. H. Coupè, W. F. Lems, M. Boers, GLORIA consortium
Dátum:2022
ISSN:0049-0172
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Seminars In Arthritis And Rheumatism. - 57 (2022), p. 1-8. -
További szerzők:El Alili, M. Cutolo, Maurizio Opris, Daniela (1976-) (reumatológus) Da Silva, J. A. P. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Buttgereit, Frank Masaryk, Pavol Bos, Reinhard Kok, Marc R. Paolino, Sabrina Coupé, V. M. H. Lems, Willem F. Boers, Maarten GLORIA Trial consortium
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM079018
035-os BibID:(PMID)31132016
Első szerző:Hartman, Linda
Cím:Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial / L. Hartman, R. Bos, F. Buttgereit, M. Güler-Yuksel, R. Ionescu, M. R. Kok, W. F. Lems, M. Micaelo, D. Opris-Belinski, A. Pusztai, E. J. F. Santos, J. A. P. Da Silva, Z. Szekanecz, K. Zeiner, D. Zhang, M. Boers
Dátum:2019
ISSN:0300-9742
Tárgyszavak:Orvostudományok Klinikai orvostudományok szerkesztői levél
folyóiratcikk
Megjelenés:Scandinavian Journal Of Rheumatology. - 48 : 4 (2019), p. 340-341. -
További szerzők:Bos, Reinhard Buttgereit, Frank Güler-Yuksel, M. Ionescu, Ruxandra Kok, Marc R. Lems, Willem F. Micaelo, M. Opris, Daniela (1976-) (reumatológus) Karancsiné Pusztai Anita (1989-) (tudományos segédmunkatárs) Santos, E. J. F. Da Silva, J. A. P. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Zeiner, K. Zhang, Di Boers, Myra
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM076711
035-os BibID:(cikkazonosító)e000756
Első szerző:Unger, Julia
Cím:Workforce requirements in rheumatology : a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider / Julia Unger, Polina Putrik, Frank Buttgereit, Daniel Aletaha, Gerolamo Bianchi, Johannes W. J. Bijlsma, Annelies Boonen, Nada Cikes, João Madruga Dias, Louise Falzon, Axel Finckh, Laure Gossec, Tore K. Kvien, Eric L. Matteson, Francisca Sivera, Tanja A. Stamm, Zoltan Szekanecz, Dieter Wiek, Angela Zink, Christian Dejaco, Sofia Ramiro
Dátum:2018
Megjegyzések:Objective?To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology. Methods?A systematic literature review (SLR) was performed in key electronic databases (1946?2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted. Key general as well as specific need/demand and supply factors for workforce calculation in rheumatology were identified. The workforce prediction risk of bias tool was developed and applied to existing workforce studies in rheumatology. Results?In total, 14 studies in rheumatology and 10 studies in other medical fields were included. Studies used a variety of prediction models based on a heterogeneous set of need/demand and/or supply factors. Only two studies attempted empirical validation of the prediction quality of the model. Based on evidence and consensus, the newly developed risk of bias tool includes 21 factors (general, need/demand and supply). The majority of studies revealed high or moderate risk of bias for most of the factors. Conclusions?The existing evidence on workforce prediction in rheumatology is scarce, heterogeneous and at moderate or high risk of bias. The new risk of bias tool should enable future evaluation of workforce prediction studies. This review informs the European League Against Rheumatism points to consider for the conduction of workforce requirement studies in rheumatology.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Rheumatic and Musculoskeletal Diseases. - 4 : 2 (2018), p. 1-19. -
További szerzők:Putrik, Polina Buttgereit, Frank Aletaha, Daniel Bianchi, Gerolamo Bijlsma, Johannes W. Boonen, Annelies Cikes, Nada Dias, João Madruga Falzon, Louise Finckh, Axel Gossec, Laure Kvien, Tore K. Matteson, Eric L. Sivera, Francisca Stamm, Tanja A. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Wiek, Dieter Zink, Angela Dejaco, Christian Ramiro, Sofia
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.